Stock AnalizEdgewise Therapeutics, Inc. EWTX
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Edgewise Therapeutics, Inc. (EWTX) is a healthcare company listed in the US with a market value of about $5.0B.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 5.6, a 5-year average ROIC of -22%.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$168M | -$134M | -$100M | -$68M | -$43M | -$17M |
| Free cash flow | -$144M | -$110M | -$98M | -$58M | -$34M | -$15M |
| EPS (diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-23.17 |
| Net margin | — | — | — | — | — | — |
| ROIC | -28.7% | -27.1% | -27.9% | -16.1% | -12.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $55.42, 21% above the current price; targets range from $36.00 to $85.00; the consensus rating is “Strong buy”; expected EPS is $7.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Edgewise Therapeutics’s P/E ratio?
About 5.6, based on the last twelve months of diluted earnings per share.
Does Edgewise Therapeutics pay a dividend?
Not currently.
Is Edgewise Therapeutics a good stock to buy?
We do not give buy or sell advice. Edgewise Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.